U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07242599) titled 'Ongericimab Injection Reducing Recurrence of Ischemic Stroke' on Nov. 17.
Brief Summary: The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C < 1.4 mmol/L).
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Ischemic Cerebral Infarction
Intervention:
COMBINATION_PRODUCT: High target group
Standardized lipid-lowering therapy according to the Chinese Stroke Association Guidelines for Clini...